Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03323398 |
|
Recruitment Status :
Terminated
(This study was halted prematurely because the efficacy endpoints were not met for either treatment arm.)
First Posted : October 27, 2017
Last Update Posted : July 11, 2022
|
Sponsor:
ModernaTX, Inc.
Information provided by (Responsible Party):
ModernaTX, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | August 18, 2021 |
| Actual Study Completion Date : | August 18, 2021 |
| Certification/Extension First Submitted : | July 7, 2022 |